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BERRY PREPARATIONS AND EXTRACTS 
This application is a continuation-in-part utility patent 
application which claims priority to US. patent application 
Ser. No. 12/088,156 ?led on Mar. 26, 2008 (issued as US. 
Pat. No. 7,964,223), which in turn is a national stage appli 
cation of international patent appl. no. PCT/U S06/ 37237 ?led 
on Sep. 26, 2006 and claiming the bene?t of priority in US. 
Provisional PatentAppl. Ser. No. 60/720,892 ?led on Sep. 27, 
2005, the disclosures of each of which are incorporated in 
their entirety herein by reference. 
TECHNICAL FIELD 
The present invention relates to compositions having anti 
oxidant and anti-in?ammatory activity, derived from a berry. 
In particular, the invention relates to a method for deriving an 
extract having antioxidant and anti-in?ammatory activity 
from a berry, and to formulated compositions derived by the 
method for oral and topical administration. Still further, the 
invention provides methods and compositions for treatment 
of in?ammation, oxidative stress, or cancer comprising 
administering an effective amount of the composition of the 
invention. 
BACKGROUND OF THE INVENTION 
Polyphenolics (also known as phenolics) are metabolites 
found in plants, fruits, and vegetables. Phenolics have a num 
ber of functions including acting as free radical scavengers. 
Thus, phenolics disrupt many biological processes. The most 
notable type of phenolics are ?avonoids which consist of 
proanthocyanidins, anthocyanidins, ?avones, ?avonols and 
their glycosides (Macheix, 1990). Anthocyanins are respon 
sible for the red, purple, and blue colors of many fruits and 
vegetables. The term anthocyanin refers to a group of pig 
ments found in plants, fruits, and vegetables that can be 
classi?ed as both ?avonoid and phenolic. Anthocyanins are 
not found in animals, microorganisms, or marine plants. It is 
thought that anthocyanins function by attracting insects to 
promote pollination but also to protect the plants from dam 
age caused by ultraviolet (UV) radiation. Anthocyanins are 
glycosides of polyhydroxyl and polymethoxyl derivatives of 
2-phenylbenzopyrylium or ?avylium salts, and are soluble in 
water. The anthocyanins are electron de?cient, and are there 
fore are strong scavengers for reactive oxygen species (ROS) 
such as free radicals. Although there are hundreds of different 
anthocyanins found in nature, six anthocyanin compounds 
predominate including: delphinidin, petunidin, cyanidin, pel 
argonidin, peonidin, and malvidin. The daily intake of antho 
cyanins in the United States is about 180-215 mg/day, and 
constitute the largest intake of phenolic compounds (Hertog, 
1 993). 
Anthocyanins originally drew interest due to their role in 
color degradation in fruits, and their potential use as natural 
food colorants. More recently, anthocyanins have received 
attention because of their possible health bene?ts as natural 
antioxidant and anti-in?ammatory compounds, and poten 
tially as anti-cancer compounds. Antioxidant property, 
effects, or activity refers to compositions that inhibit, reduce, 
or reverse oxidation or the effects of oxidation, such as for 
example the oxidative process caused by free radicals. A free 
radical may be any chemical species that includes one or more 
unpaired electrons, and without limitations includes chemi 
cals such as hydroxyl radical, superoxide radical, nitric oxide, 
and nitrogen dioxide. Examples of conditions involving free 
radical oxidative damage include, but are not limited to, 
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aging, disease, stress, ultraviolet radiation, exercise, cancer, 
smoking, atherosclerosis, and chronic in?ammation. Studies 
showed that antioxidant activity of cyanidins was greater than 
that of vitamin E and Trolox, and comparable to that of 
butylated hydroxytoluene (BHT) and butylated hydroxyani 
sole (BHA) (Wang et al., 1997; Rice-Evans et al., 1995; Liu et 
al., 2002; Proteggente et al., 2002; Wang et al., 1999). 
In?ammation, or the biological state of being in?amed, is 
generally characterized by pain, redness, and swelling, and 
may result from physical causes such as injury, chemical 
causes such as exogenous substances including toxins, or 
biological causes such as infection by a virus, a bacteria, a 
parasite, or other disease-causing agent. As examples, various 
conditions associated with in?ammation of the gastrointesti 
nal tract are known, including but not limited to acute or 
chronic conditions or diseases such as in?ammatory bowel 
disease, gastroesophageal re?ux disease, diarrhea, radiation 
induced enteritis, chemotherapy-induced enteritis, Crohn’s 
disease, irritable bowel syndrome, diverticulitis, ulcers, coli 
tis, viral infection, bacterial infection, and parasitic infection 
or infestation. In individuals a?Iicted with the above and 
similar conditions, affected cells such as dendritic cells, 
monocytes, macrophages, ?broblasts, endothelial cells, and T 
cells release causative agents, including cytokines such as 
interleukins (IL), tumor necrosis factor (TNF), interferons 
(IFN), and the like which trigger in?ammation and/or an 
in?ammatory response. Cytokines important in in?ammation 
include, but are not limited to, IL-1, IL-6, IL-12, TNF-(x, and 
IFN-(x. Anti-in?ammatory properties, effects, or activity 
refers to reducing in?ammation and promoting healing of 
cells and tissues subject to in?ammation and/or in?ammatory 
processes. 
Anti-cancer property, effect, or activity refers to a property 
of a substance, chemical, or material that can slow the prolif 
eration of tumor cells (termed anti-proliferative effect), or kill 
tumor cells (termed cytotoxic effect). Recent studies have 
shown also that berries such as black raspberries possess 
cancer-preventing properties at both in-vitro and in-vivo lev 
els (Kresty et al., 2001; Castro et al., 2002; Xue et al., 2001; 
Huang et al., 2002; Rodrigo et al, in press; US. patent appli 
cation Ser. No. 10/951,413). In particular, anthocyanins have 
been shown to demonstrate a wealth of chemopreventive 
properties (Hecht et al., in press; Liu et al., 2002; Katsube et 
al., 2003; Hu et al., 2003). 
However, anthocyanin compounds are inherently unstable 
both in vivo and in vitro, and tend to degrade over time, 
negating any health or medical bene?ts associated therewith 
(Rubinskiene et al., 2005; Nielsen et al., 2003; Morais et al., 
2002). A need in the art therefore exists for methods for 
preparing compositions from anthocyanin-containing fruits 
such as berries which provide a stable anthocyanin content. 
Still further, there is a need for compositions including such 
stable anthocyanin compositions to provide health and medi 
cal bene?ts to individuals utiliZing them. In particular, com 
positions formulated for oral administration and topical 
administration are described herein. However, it will be 
appreciated that other formulations are contemplated and can 
be derived by the skilled artisan from the teachings herein 
using methods known in the art, including injectable formu 
lations. Accordingly, the present invention contemplates also 
injectable formulations including, but not limited to, solu 
tions, suspensions, emulsion, microemulsions, micelles, lipo 
somes, nanoparticles, microparticles, implants, depots, and 
polymer conjugates. 
SUMMARY OF THE INVENTION 
The present invention provides methods for deriving stable 
compositions from blackberries, and compositions incorpo 
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rating such stable compositions. In one aspect, a method is 
provided for preparing a composition having antioxidant and 
anti-in?ammatory activity, comprising exposing a berry to a 
solvent composition having a pH of from about 1 to about 3, 
adding a cryoprotectant, and recovering a berry extract hav 
ing a stable anthocyanin content. The berry may be a black 
berry. In one embodiment, the method comprises the steps of 
physically disrupting a quantity of berries, exposing the 
physically disrupted berries to the solvent composition, 
recovering a berry extract having a pH of from about 1.0 to 
about 4.5, and adding a cryoprotectant. The cryoprotectant is 
added in an amount of at least 2: 1 (w/w) cryoprotectantzberry 
extract. The berry extract so provided typically comprises at 
least one stable anthocyanin in an amount effective to provide 
antioxidant and anti-in?ammatory activity. In another 
embodiment, the recovered berry extract has a pH of about 
3.5. The physically disrupted berries may be dewatered prior 
to being exposed to the solvent composition, after being 
exposed to the solvent composition, or both. 
In another aspect, the present invention provides stabilized 
compositions having antioxidant and anti-in?ammatory 
activity, prepared by the method of the invention as described 
above. In one embodiment, a composition is provided having 
antioxidant and anti-in?ammatory activity, comprising a 
berry extract having at least one stable anthocyanin in an 
amount effective to provide antioxidant and anti-in?amma 
tory activity. The berry extract is provided by the steps of 
physically disrupting a quantity of berries and exposing the 
physically disrupted berries to a solvent composition having 
a pH of from about 1 to about 3, and adding a cryoprotectant, 
which stabilizes the at least one anthocyanin. The cryopro 
tectant is added in an amount of at least 2:1 (w/w) cryopro 
tectant:berry extract. The berry extract may be derived from a 
blackberry. Compositions comprising the berry extract of the 
present invention, formulated for oral and/ or topical admin 
istration, are provided also, including without limitation 
nutritional supplements, capsules, tablets, chewing gum, 
lotions, creams, mucoadhesive gels, vanishing lotions, van 
ishing creams, and the like. 
In yet another aspect, the present invention provides methods 
for treatment of in?ammation, oxidative stress, or cancer in a 
mammal in need thereof, comprising administering an effec 
tive amount of the composition of the invention. Still yet 
further, another aspect of the invention is compositions com 
prising a therapeutically effective amount of the composition 
of the invention, formulated in a pharmaceutically acceptable 
vehicle. The composition may be provided in combination 
with additional anticancer agents, additional anti-oxidant 
agents, and/ or additional anti-in?ammatory agents. 
As should be appreciated, the embodiments shown and 
described herein are an illustration of one of the modes best 
suited to carry out the invention. It will be realized that the 
invention is capable of other different embodiments and its 
several details are capable of modi?cation in various, obvious 
aspects all without departing from the invention. Accord 
ingly, the drawings and descriptions will be regarded as illus 
trative in nature, and not as restrictive. Unless otherwise 
indicated, all patents, patent applications, and non-patent 
documents referenced in the present disclosure are incorpo 
rated herein by reference in their entirety. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The accompanying drawings incorporated in and forming 
a part of the speci?cation, illustrate several aspects of the 
present invention and together with the description serve to 
explain the principles of the invention. In the drawings: 
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FIG. 1 shows percent weight increase of active blackberry 
powder as a function of time when stored at 25° C. and at 4° 
C.; 
FIG. 2 depicts a standard HPLC chromatogram of a black 
berry extract made according to the present invention; 
FIGS. 3A and 3B show the stability of anthocyanins as a 
function of pH and time; 
FIG. 4 shows the stability of a speci?c anthocyanin (cya 
nidin-3-glucoside) in a blackberry preparation made accord 
ing to the present invention as a function of time and storage 
condition; 
FIGS. 5A and 5B show the stability of anthocyanins in 
blackberry preparations made according to the present inven 
tion as a function of time and temperature; 
FIG. 6 presents a dissolution pro?le of enteric-coated hard 
capsules containing a berry composition according to the 
present invention; 
FIG. 7 shows a dissolution pro?le of enteric-coated hard 
capsules containing a berry extract according to the present 
invention; 
FIG. 8 shows inhibition of proliferation of HT-29 cells by 
a blackberry extract according to the present invention; and 
FIG. 9 shows inhibition of IL-12 release from murine den 
dritic cells by a blackberry extract according to the present 
invention. 
Reference will now be made in detail to the present pre 
ferred embodiment of the invention, an example of which is 
illustrated in the accompanying drawings. 
DETAILED DESCRIPTION OF THE INVENTION 
Blackberries and raspberries, sometimes referred to as 
“brambles”, are a species of fruit in the genus Rubus. Rubus is 
quite diverse and has 12 subgenera with several of the sub 
genera having more than a hundred species. In the United 
States, R. allegheniensis, R. argulus, R. cuneifolius, R. 
Canadensis, and R. lrivialis are the dominant Rubus species. 
Blackberries belong to the subgenus Eubalus, and have much 
greater complexity than raspberries in terms of genetic back 
ground, growth characteristics, and number of species. 
Blackberries are native to Asia, Europe, North and South 
America. They have been grown in Europe for over 2000 
years as food and for medical applications. Blackberries grow 
in three different forms: trailing, semi-erect, and erect. In the 
eastern half of the United States, the dominate form is the 
erect including the thorny types, Cherokee, Comanche, Chey 
enne, Darrow, Illini Hardy Blackberry, Shawnee, and Choc 
taw. The thornless cultivars include Hull, Chester, Navaho, 
and Arapaho. Other types of blackberries include, but are not 
limited to, Eldorado, Ebony King, Raven, Ranger, Hedrick, 
Bailey, and Brazos. Semi-erect blackberries requiring a trellis 
for production include Black Satin, Chester, Dirksen, Hull 
Thornless, Smoothstem, and Thornfree. In the Paci?c North 
west, blackberries are often called Marionberries. Other ber 
ries that have genetic similarity to blackberries include Boy 
senberry, Loganberry, Olallieberry, and Youngberry. A 2002 
report by the USDA lists the total US production of all black 
berry types to be about 56 million pounds grown on 8370 
acres. According to the USDA, of the blackberries harvested 
in the US, about 40% are used for jams and jellies, 25% for 
bakery products, 23% frozen or canned, and the 12% for 
juices or other food. 
Tsao et al. (2003) showed that, relative to other fruits, 
blackberries have high concentrations of polyphenolics such 
as anthocyanins with as much as 1923 ug/ g wet fruit. Sellap 
pan et al. (2002) showed that blackberries had high concen 
trations of ellagic acid; Chocktaw had 33.81 mg/ 100 g berry 
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and Kiowa had 30.01 mg/ 100 g berry. Blackberries were also 
found to contain ?avonoids, with the major ?avonoid, cat 
echin, present in Choctaw at 312.86 mg/ 100 g berry. Sellap 
pan showed that the average total anthocyanin and polyphe 
nolic content in blackberries was 116591858 mg/100 g 
berry and 4865319713 mg/ 100 g berry, respectively. 
Accordingly, in one embodiment the present invention 
describes methods for deriving stable compositions from 
blackberries, and compositions made by those methods. 
However, it will easily be understood by those skilled in the 
art that the methods and compositions taught in this invention 
apply to many other types of fruits, plants, and vegetables 
having an anthocyanin content, including but not limited to: 
strawberries, black raspberries, apple, crabapple, chokeberry, 
Hawthorn, Juneberry, Loquat, pear, apricot, cherry, plum, 
peach, various other raspberries, cloudbeny, wineberry, 
salmonberry, bearberry, bilberry, cranberry, huckleberry, bar 
berry, currant, elderberry, gooseberry, hackberry, honey 
suckle, nannyberry, sheepberry, sea grape, wolfberry, crow 
beny, goumi, kiwi, various other grapes, thimbleberry, 
salmonberry, various types of melons such as watermelon, 
?g, lime, avocado, feijoa, guava, kumquat, longan, lychee, 
passion fruit, and pineapple. 
In one aspect, the present invention provides a method for 
preparing a composition having antioxidant and anti-in?am 
matory activity, comprising exposing a berry to a solvent 
composition having a pH of from about 1 to about 3, adding 
a cryoprotectant, and recovering a berry extract having a 
stabilized anthocyanin content. As discussed above, the berry 
may be a blackberry. In one embodiment, the method com 
prises the steps of: physically disrupting a quantity of berries, 
exposing the physically disrupted berries to the solvent com 
position, recovering a berry extract having a pH of from about 
1.0 to about 4.5, and adding a cryoprotectant. Suitable cryo 
protectants include, but are not limited to, monosaccharides 
such as glucose, fructose, maltose, ribose, mannose, and 
xylose, disaccharides such as trehalose, sucrose, myoinositol, 
phosphorylated inositols, and glycerol, polysaccharides such 
as hydroxyethyl starch and other starches, dextran, and hyalu 
ronic acid, and polymers such as polyvinylpyrrolidone, algi 
nates, carrageenan, cyclodextrins, polyvinyl alcohol, cellu 
lose-derivatives such as carboxymethyl cellulose, methyl 
cellulose, hydroxypropyl cellulose, hydroxypropylmethyl 
cellulose, xanthan gum, and chitosan. It will be appreciated 
that the ?nal pH of the extract will depend on both the con 
centration of the berry extract in the solvent composition and 
on the speci?c solvent composition used for extraction. The 
berry extract so recovered typically comprises at least one 
stabilized anthocyanin in an amount effective to provide anti 
oxidant and anti-in?ammatory activity. In another embodi 
ment, the recovered berry extract has a pH of about 3.5. The 
stabilized anthocyanin may be a delphinidin, a petunidin, a 
cyanidin, a pelargonidin, a peonidin, a malvidin, or any com 
bination thereof. 
The physically disrupted berries may be exposed to a sol 
vent composition comprising an alcohol and at least one acid, 
with the acid provided in a suf?cient amount whereby the 
solvent composition has a pH of from about 1 to about 3. The 
acid may be provided in an amount of from about 0.005% to 
about 3% (v/v) of the alcohol. In one embodiment, the acid is 
provided in an amount of from about 0.01% to about 2% of 
the alcohol (v/v). In yet another embodiment, the acid is 
provided from about 0.01% to about 1% of the alcohol (v/v). 
Any of a number of alcohols may be suitable for the present 
invention, including, but not limited to, lower chain alcohols 
such as methanol, ethanol, propanol, butanol, and mixtures 
thereof. The acid may be any acid suitable for providing the 
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desired pH for the solvent composition, including, but not 
limited, to hydrochloric acid, acetic acid, citric acid, lactic 
acid, tri?uoroacetic acid, aspartic acid, glutamic acid, sulfur 
containing acids such as sulfonic acid, phosphoric acid, 
maleic acid, and mixtures thereof. In yet another embodi 
ment, the alcohol can be replaced with a suitable ketone or a 
suitable halogenated ole?n, such as acetone, chloroform, 
methylene chloride, or mixtures thereof. 
The physically disrupted berries may be dewatered to a 
residual water content of up to 20% (w/v) prior to being 
exposed to the solvent composition, after being exposed to the 
solvent composition, or both. In one embodiment, the physi 
cally disrupted berries are dewatered to a residual water con 
tent of up to 10% (w/v). It will be appreciated that any suitable 
method may be employed for dewatering, such as heating or 
centrifuging a berry puree to remove water, followed by 
crushing the dried berry puree to a powder. Typically, a pow 
der in accordance with the present invention is prepared by 
lyophilization or freeze-drying, i.e., freezing followed by 
removal of water by sublimation. Bene?cially, freeze-drying 
provides a chemically and physically stable, free-?owing dry 
powder. 
In another aspect, the present invention provides composi 
tions having antioxidant and anti-in?ammatory activity, pre 
pared by the method of the invention as described above. In 
one embodiment, a composition is provided having antioxi 
dant and anti-in?ammatory activity, comprising a berry 
extract having at least one stabilized anthocyanin in an 
amount effective to provide antioxidant and anti-in?amma 
tory activity. The berry extract may be provided by the steps 
of physically disrupting a quantity of berries, exposing the 
physically disrupted berries to a solvent composition, and 
adding a cryoprotectant, which stabilizes the at least one 
anthocyanin. Suitable cryoprotectants include, but are not 
limited to, monosaccharides such as glucose, fructose, mal 
tose, ribose, mannose, and xylose, disaccharides such as tre 
halose, sucrose, myoinositol, phosphorylated inositols, and 
glycerol, polysaccharides such as hydroxyethyl starch and 
other starches, dextran, and hyaluronic acid, and polymers 
such as polyvinylpyrrolidone, alginates, carrageenan, cyclo 
dextrins, polyvinyl alcohol, cellulose-derivatives such as car 
boxymethyl cellulose, methyl cellulose, hydroxypropyl cel 
lulose, hydroxypropylmethyl cellulose, xanthan gum, and 
chito san. The berry extract may be derived from a blackberry. 
In one embodiment, the berry extract has a pH of from about 
1 .0 to about 4.5. In another embodiment, the berry extract has 
a pH of about 3.5. The stabilized anthocyanin may be a 
delphinidin, a petunidin, a cyanidin, a pelargonidin, a peoni 
din, a malvidin, and combinations thereof. 
The solvent composition may comprise an alcohol and at 
least one acid, wherein the acid is provided in an amount 
suf?cient wherein a pH of the solvent composition is from 
about 1 to about 3. The acid may be provided in an amount of 
from about 0.005% to about 3% (v/v) of the alcohol. The 
alcohol may be any suitable alcohol, including but not limited 
to lower chain alcohols such as methanol, ethanol, propanol, 
butanol, and mixtures thereof. The acid may be any acid 
suitable for providing the desired pH of the solvent compo 
sition, including, but not limited to, hydrochloric acid, acetic 
acid, citric acid, lactic acid, tri?uoroacetic acid, aspartic acid, 
glutamic acid, formic acid, phosphoric acid, maleic acid, and 
combinations thereof. Optionally, in place of the alcohol a 
suitable ketone or a suitable halogenated ole?n may be used, 
such as acetone, chloroform, methylene chloride, and mix 
tures thereof. As discussed above, the physically disrupted 
berries may be dewatered to a water content of up to 20% 
US 8,367,126 B2 
7 
(w/v), such as by freeze-drying, either prior to exposing to the 
solvent composition, after exposing to the solvent composi 
tion, or both. 
A variety of formulations for oral and/ or topical adminis 
tration are contemplated for the composition of the present 
invention. In one embodiment, a formulation for oral admin 
istration is provided, comprising the berry extract in an 
amount of from about 3% (w/w) to about 90% (w/w). In 
another embodiment, a formulation for topical administration 
is provided, comprising the berry extract in an amount of from 
about 1% (w/w) to about 20% (w/w). It will be appreciated by 
the skilled artisan that a large number of topical and oral 
formulations are known in the art, such as nutritional supple 
ments, capsules, enteric-coated capsules, ?lm-coated cap 
sules, tablets, enteric-coated tablets, ?lm-coated tablets, 
chewing gums, lotions, creams, mucoadhesive gels, vanish 
ing lotions, vanishing creams, and the like. Other ways to 
apply a composition topically formulations are known, 
including but not limited to: sprays, ointments, gels, patches, 
and needle-free devices that deliver their contents by diffu 
sion, mechanical or gas-driven energy. The making of such 
formulations and/or devices is well within the ability of the 
skilled artisan, and such formulations and methods are con 
templated also by the present invention. 
For example, it is known to provide compositions in emul 
sion or microemulsion form, as lotions and/or creams. A 
lotion refers to a semi-viscous emulsion that is meant to be 
applied to the skin. A cream refers to a more viscous emulsion 
that is also meant to be applied to the skin. Lotions and creams 
may be of the oil-in-water or water-in-oil type. In one 
embodiment of the present invention, lotions and creams of 
the oil-in-water type are provided which stabilize a compo 
sition according to the present invention, and/or promote its 
penetration into or through the skin layers. 
An emulsion refers to a biphasic opaque mixture of two 
immiscible liquids stabilized by a surfactant. Emulsions are 
thermodynamically unstable systems, and usually require the 
application of high-torque mechanical mixing or homogeni 
zation to produce dispersed droplets in the range of about 0.2 
to 25 pm. In contrast, a microemulsion is a stable biphasic 
mixture of two immiscible liquids stabilized by a surfactant 
and usually a co-surfactant. Microemulsions are thermody 
namically stable, isotropically clear, form spontaneously 
without excessive mixing, and have dispersed droplets in the 
range of about 5 nm to 140 nm. Both microemulsions and 
emulsions can be made as water-in-oil or oil-in-water sys 
tems. In a water-in-oil system, the dispersed phase is water 
and the continuous phase is oil. In an oil-in-water system, the 
dispersed phase is oil and the continuous phase is water. 
Whether water-in-oil or oil-in-water systems will form is 
largely in?uenced by the properties of the surfactant. The use 
of surfactants that have hydrophilic-lipophilic balances 
(HLB) of about 3-6 tend to promote the formation of water 
in-oil microemulsions while those with HLB values of about 
8-18 tend to promote the formation of oil-in-water micro 
emulsions. 
Formulations contemplated for oral administration 
directly to the gastrointestinal tract include, but are not lim 
ited to, nutritional supplements, capsules, enteric-coated cap 
sules, ?lm-coated capsules, tablets, enteric-coated tablets, 
?lm-coated tablets, chewing gums, caplets, solutions, and 
suspensions. It is envisioned that more novel particle-based 
suspensions for oral administration can be produced, such as 
emulsions, microemulsions, nanoparticle or microparticle 
suspensions. It is also contemplated in this invention that a 
formulation for oral administration may be prepared that is 
delivered to and retained in the mouth, whereby the contents 
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and/ or the active ingredient primarily drain into the stomach. 
Formulations meeting these criteria include, but are not lim 
ited to, chewing gums, gels, sprays, lozenges, lollipops or 
other candies, rapidly dissolving strips, and the like. In one 
embodiment, the formulation for oral administration is a tab 
let or hard-gelatin capsule. In another embodiment, the for 
mulation is coated with a substance to control the rate or 
location of disintegration, i.e., an enteric-coated or ?lm 
coated formulation. 
The present invention contemplates providing enteric 
coated oral formulations. An enteric-coating refers to a coat 
ing on an oral dosage form that is meant to cause the oral 
dosage form to remain intact in the lower pH of the stomach, 
but disintegrate once the dosage form reaches the higher pH 
of the intestines including the small intestines, large intes 
tines, colon, or rectum. The most common enteric coatings 
are those that remain intact (undissociated) in the low pH of 
the stomach, but ionize when the pH is above pH 4-5, pH 5-7, 
or even above pH 7. Common enteric-coating materials 
include, but are not limited to, cellulose acetate phthalate, 
polyvinyl acetate phthalate, hydroxypropylmethyl cellulose 
phthalate, cellulose acetate trimellitate, carboxymethyl eth 
ylcellulose, and hydroxypropyl methylcellulose acetate suc 
cinate, and polymethacrylates (methacrylic acid copolymer) 
including EUDRAGIT-based polymers. It is also contem 
plated to provide ?lm-coated oral formulations. A ?lm-coat 
ing typically targets the coated substance to the colon by 
remaining undissociated or stable until a pH 7 environment is 
reached. Film-coating materials to achieve this goal include, 
but are not limited to, EUDRAGIT-based polymers that are 
soluble in intestinal ?uid at a pH greater than 7, pectin, amy 
lose, and chitosan-based polymers. 
It is also envisioned that a colon or tumor-speci?c ?lm 
coating can be used on the oral dosage form that effectively 
serves to increase the delivered concentration of the compo 
sition of the present invention by selective removal of the 
coating by an endogenous enzyme present in the target tissue 
of the small intestines, large intestines, colon, or rectum. 
Alternatively, it is envisioned that tumors in the colon or 
rectum can be targeted by coating the dosage form with a 
ligand speci?c for the tumor cell surface, i.e., without limita 
tion an antibody or binding fragment thereof. 
A chewing gum is a ?avored composition that is meant to 
deliver a ?avor or other substance by chewing. The primary 
part of chewing gum is the gum base, which is a non-nutritive 
substance. The gum base may consist of any one or more of 
the following; an elastic ingredient, a resin that acts as a 
binder and softener, a plasticizer, ?llers, a sweetener or ?a 
voring agent, and an antioxidant. As an example, Subpart G 
titled “Gum, Chewing Gum Bases and Related Substances” 
from The Code of Federal Regulations (Title 21, Volume 3, 
Subchapter B) lists ingredients that may be used in gums, 
including arabinogalactan, natural gum bases including 
chicle, chiquibul, crown gum, gutta hang kang, massaranduba 
balata, massaranduba chocolate, nispero, rosidinha, Venezu 
elan chicle, jelutong, leche capsi (sorva) perillo, leche de 
vaca, niger gutta, tunu, chilte, natural rubber (smoked sheet 
and latex solids), synthetic substances such as butadiene 
styrene rubber, isobutylene-isoprene copolymer, para?in, 
petroleum wax, petroleum wax synthetic, polyethylene, poly 
isobutylene, and polyvinyl acetate, plasticizing materials 
including glycerol ester of partially dimerized rosin, glycerol 
ester of partially hydrogenated gum or wood rosin, glycerol 
ester of polymerized rosin, glycerol ester of gum rosin, glyc 
erol ester of tall oil ro sin, glycerol ester of wood rosin, lanolin, 
methyl ester of rosin partially hydrogenated, pentaerythritol 
ester of partially hydrogenated gum or wood rosin, rice bran 
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wax, stearic acid, sodium and potassium stearates, synthetic 
and natural terpene resins, antioxidants including butylated 
hydroxyanisole, butylated hydroxytoluene, propyl gallate, 
carrageenan, carrageenan with polysorbate 80, salts of carra 
geenan, furcelleran, salts of furcelleran, gellan gum, and xan 
than gum. Of course, compositions in addition to those of the 
present invention may be included as is known in the art to 
provide desirable attributes for the gum, such as enjoyment 
(taste, mouth-feel, and the like), breath freshening, dental 
care, and oral care. 
Still further, the compositions of the present invention may 
be provided along with a mucoadhesive polymer excipient, 
for direct delivery to a mucosal surface and also for transmu 
cosal delivery into systemic circulation. Brie?y, mucoadhe 
sive polymer excipient refers to a polymer that has the ability 
to adhere to mucin. Typically, for the compositions of the 
present invention a mucoadhesive acidic polymer excipient is 
used, which when dissolved or suspended in water results in 
an acidic pH. In one embodiment, the mucoadhesive polymer 
will provide a polymer solution or suspension having a pH of 
from about 1 to about 4.5. The polymer may be non-ionic or 
anionic. Mucoadhesive polymer excipients will typically be 
selected which also control the rate of release of the active 
ingredient from the gel by providing a controlled rate of 
polymer rehydration. The mucoadhesive polymer excipient 
may be present in the dosage form in one embodiment in a 
weight percentage between 5-50%. In another embodiment, 
the excipient is present in a weight percentage between 
5-20%. In yet another embodiment, the excipient is present in 
a weight percentage between 5-10%. As non-limiting 
examples, the mucoadhesive polymer excipient may be 
selected from one or more of the following polymers: poly 
acrylic acid, crosslinked polyacrylic acid, polyvinyl pyrroli 
done, cross-linked polyvinyl pyrrolidone, polymethacrylic 
acid, polymethacrylic-acid co-polymers, carboxymethyl cel 
lulose, cellulose or derivatives thereof, or alginate. 
Of course, additional substances may be included in the 
formulations of the present invention to provide additional 
desired properties, such as sweeteners or preservatives. 
Sweeteners may be of natural original or synthetic, and may 
include, but are not limited to, fructose, glucose, glycerol, 
lactitol, maltitol, maltose, sorbitol, xylitol, saccharin, aspar 
tame, cyclamate, sucralose, or acesu?ame potassium, or mix 
tures thereof. Preservatives are natural or synthetic chemicals 
that are added to hinder spoilage, whether caused by micro 
bial growth, or unwanted chemical changes such as, but not 
limited to, hydrolysis or oxidation. Suitable preservatives 
may include, but are not limited to, benzoic acid, sorbic acid, 
benzyl alcohol, benzethonium chloride, butyl paraben, cet 
rimide, chlorobutanol, cresol, ethyl paraben, phenol, phe 
noxyethanol, propylene glycol, sodium benzoate, thimersol, 
methyl paraben, propyl paraben, or mixtures thereof. 
Still yet further, the present invention provides a method of 
treating in?ammation, oxidative damage, or cancer, compris 
ing administering to a mammal such as a human in need 
thereof an effective amount of a composition as described 
above. The in?ammation may be associated with cancer, 
in?ammatory bowel disease, gastroesophageal re?ux dis 
ease, diarrhea, radiation-induced enteritis, chemotherapy-in 
duced enteritis, Crohn’s disease, irritable bowel syndrome, 
diverticulitis, ulcer, colitis, viral infection, bacterial infection, 
parasitic infection, and combinations thereof. The in?amma 
tion may be partially mediated by the release in the body of 
the mammal of at least one cytokine including, but not limited 
to, an interleukin such as IL- 1, IL-6, or IL- 1 2, or TNF-(x, and 
IFN-(x. The oxidative damage may be mediated at least par 
tially by release of a free radical in the body of the mammal. 
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The cancer may be a skin cancer, an oral cancer, a cancer of 
the eye, a cancer of a mucosal surface such as the vagina, the 
nose, and the rectum, and combinations thereof. As described 
above, the composition may be formulated for administration 
by at least one of orally, topically, and by injection. 
In yet still another aspect, the present invention provides 
compositions for treating in?ammation, oxidative damage, or 
cancer in a mammal in need thereof, comprising a therapeu 
tically effective amount of a composition as described above 
in a pharmaceutically acceptable vehicle. The composition 
may further comprise at least one additional anti-cancer 
agent, at least one additional anti-oxidant, at least one addi 
tional anti-in?ammatory agent, and combinations thereof. 
The compositions may be formulated for administration by at 
least one of orally, topically, and by injection as described 
above. 
The examples provided herein are presented in support of 
and to further illustrate the invention as described above and 
in the accompanying drawings, but are not to be considered as 
limited thereto. Citations of literature herein are incorporated 
into this disclosure by reference in their entirety unless oth 
erwise indicated. Generally, 2,2-Azinobis(3-ethylbenzothia 
zoline-6-sulfonicacid)diammonium salt (ABTS), Trolox 
(6-hydroxy-2,5,7,8-tetramethychroman-2-carboxylic acid), 
potassium persulfate, formic acid (ACS, >96%), 3-(4,5-dim 
ethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT), Folin and Ciocalteau phenol reagent and gallic acid 
(98% purity) were purchased from Sigma (St. Louis, Mo.). 
Hydrogen chloride ~l .25 M in ethanol was purchased from 
Fluka (St. Gallen, Switzerland). USP grade Ethanol (Abso 
lutei200 proof) was purchased from AAPER Alcohol and 
Chemical Co. (Shelbyville, Ky.). HPLC grade acetonitrile 
was purchased from Fisher Scienti?c (Fair Lawn, N.J.). 
EXAMPLE 1 
A blackberry puree was prepared by pulping whole black 
berries. For purposes of this disclosure, the term pulping 
refers to the process of removing the seeds and skin from 
whole fruit. However, it will be understood by those skilled in 
the art that the skin and seeds also contain many biologically 
useful substances and so it is envisioned that the skin and 
seeds may be retained for later use, or alternatively may be 
kept with the fruit pulp rather than separated. 
Blackberries were picked from the vine and placed in con 
tainers for transporting to the picking station for inspection. 
The berries were not washed in order to prevent deterioration 
of the whole berry by surface water. The seeds and skin of the 
berries were removed using a Langsenkamp type 161 Colos 
sal Pulper having two agitator arms with brushes with a 
stainless steel chamber, and stainless steel catch pan with two 
outlets (one threaded and one with a sanitary ?tting) with a 
lO-horse power, 3 phase, 60 cycle, 230/460 volt meter. Whole 
blackberries were passed through the Lagsenkamp Pulper at 
a rate of 50-75 gallons/minute to produce a homogenous 
blackberry puree free of skin and seeds. The blackberry puree 
was stored frozen at —200 C. 
EXAMPLE 2 
A VirTis Model AD2 Lyophilizer was used to freeze-dry a 
blackberry puree, prepared as described in Example 1, to 
produce a free-?owing powder. The cycle used a freezer 
temperature of —400 C., a condenser temperature of —50° C., 
and vacuum of 200 mTorr. Approximately 10 g of blackberry 
puree in a glass lyophilization vial was freeze-dried. The 
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following drying steps were used to prepare a purple cake of 
freeze-dried blackberry puree: 
TABLE 1 
Example Freeze—Drying Cycle for Blackberry Puree 
to Produce Active Pharmaceutical Powder 
Drying Temp Time Vacuum 
Steps (° C.) (min) (mTorr) 
1 —35 10 200 
2 —30 5 200 
3 —25 5 200 
4 —20 1200 200 
5 — 1 5 840 200 
6 — 1 0 10 200 
7 —5 10 200 
8 0 10 200 
9 5 120 200 
10 10 3 00 200 
1 1 15 10 200 
12 20 180 200 
Post Heating 25 90 200 
The freeze-dried blackberry puree was collected from the 
glass lyophilization vial and milled using a mortar and pestle 
to produce a free-?owing reddish-purple powder. 
EXAMPLE 3 
A Hull lyophilizer was employed to create a second 
embodiment of a dry powder of the blackberry puree. A 
partially frozen blackberry puree (Example 1) (5204 g) was 
placed into the lyophilizer on metal pans in large chunks. The 
following lyophilization cycle shown in Table 2 was used to 
dry the blackberry puree: 
TABLE 2 
Lyophilization Cycle Used to Produce 
Freeze—Dried Blackberry Powder 
Steps 
. Freeze to —40° C. 
. Raise temp to —35° C. 
. Once at —35° C., hold for 3 hr 
Set vacuum to less 150 microns 
. Raise temp to —10° C. 
. Once at —10° C., hold for 3 hr 
. Maintain vacuum of less than 150 microns 
. Raise temp to 0° C. 
. Once at 0° C., hold for 3 hr 
. Raise Temp to 5° C. 
. Once at 5° C., hold for 2.5 hr 
. Raise temp to 10° C. 
. Once at 10° C., hold for 2.4 hr 
. Raise temp to 20° C. 
. Once at 20° C., hold for 2.5 hr 
. Break vacuum 
The resulting blackberry powder weighed 559 g and was 
10.7% w/w of the initial blackberry puree that was lyo 
philized. Next, 100 g of the freeze-dried blackberry powder 
was treated under sonication with 500 mL ethanol containing 
0.01% HCl for 30 min to produce a blackberry extract having 
a pH in the range of 1.9-2.0. The suspension was ?ltered and 
the supernatant was collected in a ?ask. The supernatant was 
dried at 40° C. for 7 hr using a rotary evaporator. The recov 
ered blackberry extract weighed 19.12 g or 19.12% w/w of 
the original 100 g dried blackberry powder. 
EXAMPLE 4 
Five hundred milligram portions of blackberry powder 
prepared as described in Example 2 were evaluated for rate of 
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water sorption. Three vials were held at 25° C. and three vials 
were held at 4° C. The percentage weight increase over time 
due to water sorption was recorded for a period of 45 hr. As 
shown in FIG. 1, blackberry powder stored at 25° C. increased 
in weight by up to 10% by 30 hr, and then reached a plateau. 
In contrast, blackberry powder stored at 4° C. increased in 
weight by less than 1 .7% and reached a plateau after only 5 hr. 
EXAMPLE 5 
Two different blackberry extracts were obtained by sub 
jecting 2.5 g blackberry powder (Example 2) three times with 
either; sample A) 20 mL of ethanol/0.1% HCl or, sample B) 
20 mL of ethanol/0.01% HCl under sonication. The three 
samples for each extraction condition were collected and 
centrifuged for 10 min at 12,000 g. The supernatant was then 
?ltered to collect dark red solution. Ethanol was then removed 
at 400 C. using a rotary evaporator to obtain a dark red, 
viscous liquid. Ten (10) mL of water was added to sample A 
to produce a dark-red suspension having a pH of 1.2. Ten (10) 
mL of water was added to sample B to produce a dark-red 
suspension having a pH of 1.9. Both sample A and sample B 
were centrifuged for 10 min at 12,000 g and a ?nal dark-red 
solution referred to berry extracts. As will be discussed in 
greater detail below, the resulting compositions are enriched 
for stabilized anthocyanins. 
EXAMPLE 6 
An aliquot of freeze-dried blackberry powder (2.5 g) pre 
pared as described in Example 2 was treated under sonication 
for 30 min with 60 mL of ethanol containing 0.01% HCl. The 
supematants were collected after ?ltration and dried by rotary 
evaporation at 400 C. The dried extract was dissolved in 10 
mL of deionized water and ?ltered through a 1.0 pm nylon 
syringe ?lter. The blackberry extract had a pH of 1.9. The 
extract was either frozen at —200 C., or lyophilized to produce 
a dried blackberry extract (DBE) and then stored as a powder 
at —200 C. The average yield ofDBE was 470.44:9.27 mg per 
gram of blackberry powder. 
The blackberry extract was characterized for: i) mono 
meric anthocyanins and polymeric color measurement, ii) 
Total Phenolic Measurement, iii) Trolox Equivalent Antioxi 
dant Capacity (TEAC) Assay, and iv) anthocyanin composi 
tion. Results of characterization for i, ii, and iii are shown in 
Table 3 below. It is important to note that the values for these 
several parameters are likely in?uenced by the extraction 
ef?ciency of the berry extract. Thus, it may be appreciated by 
those skilled in the art that a different extraction protocol may 
result in a berry extract that has different composition and 
features. 
TABLE 3 
Composition and Characterization 
of Dried Blackberry Extract (DBE) 
Total Total TACC 
Anthocyanins" Phenolicsl7 Polymeric (pM TEd/ 
(mgg DBE) (mgg DBE) color (%) g DBE) 
Blackberry 6.80 z 0.31 17.32 1 0.74 2.2 11.0 66.98 1 1.27 
extract 
(11 = 3) 
“Total anthocyanins were expressed as cyanidin-3-glucoside equivalent. 
bTotal phenolics were expressed as gallic acid equivalent. 
CTAC: total antioxidant capacity measured by Trolox-equivalent antioxidant capacity assay. 
dTE: Trolox equivalent. 
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i) Monomeric Anthocyanins and Polymeric Color Mea 
surement. Monomeric anthocyanin content was determined 
by the pH-differential method of Giusti and Wrolstad (2001). 
Brie?y, samples were diluted 1:100 v/v in a 25 mM potassium 
chloride buffer (pH 1.0) and a 0.4 M sodium acetate buffer 
(pH 4.5), then read against a blank at 510 nm and 700 nm with 
1 cm path length disposable cuvettes. Total anthocyanin con 
tent was calculated using the equations below. 
A:(A510_A700) PH 1-0_(A510_A700) PH 4-5 Equation (1) 
Where: 
A is the absorbance of the diluted anthocyanin sample; 
C is the anthocyanin concentration (mg/L); 
MW is the molecular weight (449.2 for cyanidin-3-glu 
coside); 
DF is the dilution factor; and 
e is the molar absorptivity (26900 for cyanidin-3-gluco 
side). 
Color density and polymeric color were calculated using 
absorption at 420, 510 and 700 nm with and without bisul?te 
treatment. The percentage of polymeric color was determined 
by the ratio of polymerized color to color density. 
ii) Total Phenolic Measurement. Total phenolic content in 
the berry extract was estimated based on the method of 
Singleton and Rossi (1965) using gallic acid as a standard. 
Twenty (20) uL of diluted samples was added to 1.58 mL 
distilled water along with 100 uL of a 2N Forlin-Ciocalteu 
phenol reagent. All solutions were mixed thoroughly and then 
allowed to sit at room temperature for 1 min. Three hundred 
(300) pl saturated sodium carbonate solution (200 g/L) was 
then added to each sample. The absorbance was measured at 
765 nm with a Beckman UV-visible spectrophotometer after 
incubation for 2 hr at room temperature. Total phenolics were 
determined based on the standard curve generated with 0.2, 
0.4, 0.6, 0.8, and 1.0 mg/mL of gallic acid. 
iii) Trolox Equivalent Antioxidant Capacity (TEAC) 
Assay. TEAC assay for the berry extract was carried out using 
a Beckman DU640B spectrophotometer following proce 
dures described by Re et al., (1999). ABTS'+ was produced 
by reacting 7 mM ABTS with 2.5 mM potassium persulfate 
for 16 h in the dark at room temperature. The ABTS'+ solu 
tion was diluted with ethanol to an absorbance of 0.70 (10.02) 
at 734 nm and equilibrated at 30° C. Twenty (20) ul of the 
berry extract samples were added to 980 nl of diluted 
ABTS'+ solution, such that each ?nal sample produced 
between 20-80% inhibition of the blank absorbance. The 
absorbance readings were taken continuously every 6 s for 6 
min at 734 nm at 30° C. Trolox standards in ethanol with ?nal 
concentration ranging from 0 to 16.8 uM were prepared and 
assayed under the same conditions. The total antioxidant 
capacity of the berry extract was calculated and expressed as 
umol Trolox equivalent (TE) per gram of dried blackberry 
extract (DBE). The total antioxidant capacity (TAC) of the 
berry extract was determined using an improved TEAC assay 
(Re et al., 1999), which assessed the capacity ofa compound 
or sample to scavenge ABTS'+ in terms of Trolox equivalent. 
The average TAC value of the berry extract was 669811.27 
mmol TE per gram of DBE (see Table 3). 
iv) Anthocyanin Composition. HPLC-UV-MS analysis 
was performed using a X-BridgeTM C18 column (250 
mm><4.6 mm, 5 pm) (Waters) equipped with an X-BridgeTM 
C18 guard column with a Waters 2690 separation module 
equipped with a 996 photodiode array detector, and coupled 
on-line with a Waters Micromass ZMD 4000 Mass Spectrom 
eter. The mobile phase consisted of 10% formic acid (A) and 
Equation (2) 
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100% acetonitrile (B). The elution conditions were as fol 
lows: 0-45 min, linear gradient from 1 to 16% B (v/v); 46-50 
min, linear gradient from 16% to 100% B; 51-60 min, 100% 
B; post-time 5 min with 1% B; ?ow rate 1 mL/min. The 
UV-visible detection wavelength was 524 nm and the inj ec 
tion volume was 50 uL of the berry extract. The MS instru 
ment was operated at the following settings: ESP+ mode; 
capillary voltage, 3.0 kV; cone voltage, 35 V; desolvation 
temperature, 300° C.; source temperature, 100° C.; scan 
range, 100-1000 m/Z. The HPLC pro?le of the berry extract 
showed six major peaks as identi?ed as 1-6 (FIG. 2). Peak 
identi?cation was carried out based on the molecular weight 
and structural information obtained from their MS spectra, in 
addition to their retention times from HPLC-UV-vis spectra. 
It is notable that other small peaks as shown in the chro 
matogram in FIG. 2 were not identi?able by MS and their 
identity remains unknown. Cyanidin-3-glucoside (peak 1) 
was the main component (71.0%) in the berry extract with the 
respective parent and daughter ion pairs (m/Z 449/287). The 
other three major peaks (peak 4, 12.4%; peak 5, 3.5%; peak 6, 
11.6%) revealed the m/Z values of 419/287, 535/287 and 
593/287 which were identi?ed as cyanidin-3-xyloside, cya 
nidin-3 -malonylglucoside and cyanidin-3-dioxalylglucoside 
respectively, in accordance with data previously reported by 
StintZing et al. (2002). Cyanidin-3-arabinoside (peak 2) was 
also identi?ed, and was in agreement of the initial report by 
Dugo et al. (2001) using blackberry extracts. Another small 
peak (peak 3), with the respective parent and daughter ion 
pairs (m/Z 435/303), was detected in the blackberry extract 
and is being reported for the ?rst time. Based on its retention 
time, this compound has been tentatively identi?ed as del 
phinidin-3-xyloside. 
EXAMPLE 7 
An HPLC assay was used to quantify the anthocyanin 
content and stability in berry samples. The standard chro 
matogram gave two peaks corresponding to: peak 1:cyani 
din-3 -glucoside and cyanidin-3-sambubioside; and peak 
2:cyanidin-3-rutinoside and cyanidin-3-(2G-xylosylrutino 
side). A standard curve showed excellent linearity over a 
range of from 50 to 2000 ug/mL with R2>0.999 for both peak 
1 and peak 2. FIG. 3A depicts the stability of peak 1 and peak 
2 after one day at 4° C. in formulations made from pH 4.5 to 
7.5. FIG. 3B depicts the stability of peak 1 and peak 2 after 28 
days at 4° C. in formulations made at pH 3.5 or pH 4.0. 
Freeze-dried berries (prepared as described in Example 2) 
were formulated at a ?nal concentration of 10% w/w in mix 
tures having different pHs from pH 7.5, 6.5, 5.5, 4.5, 4.0, and 
3.5 and stored at 4° C. for 1 day. As shown in FIG. 3A, peak 
1 andpeak 2 showed much greater stability at lowerpH values 
after 1 day. The results of a second study are shown in FIG. 
3B. In this study, the berries were formulated at pH 3 .5 and 4. 
Formulation of the berries at pH 3.5 provided excellent sta 
bility for peak 1 (96.0:0.8%) and peak 2 (100.2:0.4%) over 
1 month at 4° C. 
EXAMPLE 8 
Blackberry extract (19.12 g, see Example 3) was dissolved 
in 500 mL water to produce a stock solution of 38.24 mg 
extract/mL. Total anthocyanin content of the 19.12 g black 
berry extract was found to be 181.3 mg/L by the pH differ 
ential method. This corresponded to a total anthocyanin con 
tent of 90.6 mg from the 19.12 g ofblackberry extract (0.5% 
w/w anthocyanins). 
US 8,367,126 B2 
15 
Two (2) mL of the blackberry extract, corresponding to 
76.48 mg extract was mixed with 8 mL of 10% mannitol and 
lyophilized to produce a dried berry extract with mannitol. 
The ?nal mannitol concentration in the solution was 8% and 
the ?nal pH ranged from 2.5 to 2.6. In addition, blackberry 
extract alone (without mannitol) was lyophilized to produce a 
dried berry extract. The lyophilization procedure for both the 
dried berry extract with mannitol and dried berry extract is 
shown in Table 4. 
TABLE 4 
Lyophilization Cycle Used to Prepare Dried Berry 
Extract and Dried Berry Extract with Mannitol 
Steps 
. Freeze to —40° C. 
. Raise temp to —35° C. 
. Once at —35° C., hold for 3 hr 
. Set vacuum to less 150 microns 
. Raise temp to —10° C. 
. Once at —10° C., hold for 15 hr 
. Maintain vacuum of less than 150 microns 
. Raise temp to 0° C. 
. Once at 0° C., hold for 3 hr 
. Raise Temp to 5° C. 
. Once at 5° C., hold for 10 hr 
. Raise temp to 5° C. 
. Once at 10° C., hold for 3.4 hr 
. Raise temp to 20° C. 
. Once at 20° C., hold for 2.5 hr 
. Break vacuum 
To observe the stability of the blackberry extract in solution 
alone, and in the presence of 8% mannitol, the extract was 
stored at 4° C. and 25° C. for 1 month. As shown in Table 5 
below, at both temperatures, the presence of 8% mannitol in 
solution was able to stabilize the retention of four different 
anthocyanins in solution designated by Peak 1 (Cn-3-gluco 
side), Peak 2 (Cn-3-arabinoside), Peak 3 (Cn-3-xyloside), 
and Peak 4 (Cn-3 -malonyl-glucoside). 
TABLE 5 
Retention of Anthocyanins in Berry Extract Solution and 
Berrv Extract with 8% Mannitol Solution Over 1 Month 
Peak 1 Peak 2 Peak 3 Peak 4 
% Retention of Anthocyanin Peak Area after 
Storage at 4° C. for 1 month 
Berry Extract 89.7 r 0.3 86.2 r 13.2 90.7 r 3.1 88.0 r 6.7 
in Solution 
Berry Extract 106.0 1 1.0 138.0 1 5.9 109.5 14.9 115.6 1 10.7 
with Mannitol 
% Retention of Anthocyanin Peak Area after 
Storage at 25° C. for 1 month 
Berry Extract 79.2 r 0.2 75.5 r 10.8 81.3 r 2.4 69.6 r 3.4 
in Solution 
Berry Extract 101.9 1 0.6 96.7 r 3.4 102.0 1 4.6 77.2 r 24.3 
with Mannitol 
To observe the stability of blackberry extract in solution 
stored at four different temperatures or conditions, blackberry 
extract solution was stored frozen at —800 C. as a control, at 4° 
C., at 250 C. in the dark, and at 250 C. with light for 90 days. 
As shown in FIG. 4, the concentration of cyanidin-3-gluco 
side remained unchanged over 90 days when the blackberry 
extract solution was frozen at —800 C. When the blackberry 
extract solution was stored at 4° C. over 90 days, there was 
about a 10% loss in the concentration of cyanidin-3-gluco 
side. In contrast, there was substantial loss of cyanidin-3 
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glucoside over 90 days when the blackberry extract solution 
was stored at 250 C., indicating that the anthocyanin was less 
stable as the temperature increased. 
To further con?rm the stability of dried blackberry extracts 
stored under various conditions and at various temperatures, 
freeze-dried blackberry powder was stored at —200 C. as a 
control, dried berry extract was stored at 4° C. and 250 C., and 
dried berry extract with mannitol stored at 4° C. and 250 C. 
The stability time points collected were at time 0, 2 weeks, 4 
weeks, and 8 weeks. 
Sample quantitation was performed by comparing the area 
of each stability data point to the area for the Time 0 point for 
each type of sample (freeze-dried blackberry powder, dried 
extract, or dried extract with mannitol). Equation 3 was used 
to calculate the concentration (mg/mL) of the sample using 
the actual weight of sample. 
Actual Weight of Sample 
Volume of Dilution 
, Equation (3) 
C = Sample concentration = 
The percent of each sample peak area relative to the peak area 
at the Time 0 point was calculated using Equation 4. 
Peak Area at Timepoint 
Peak Area at Time 0 
CTimeO Equation (4) 
% Peak Area = X 100 
CTimepoint 
As shown in FIG. 5A, the Cn-3-glucoside in the freeze 
dried blackberry powder stored at —200 C. was stable for at 
least eight weeks. Likewise, Cn-3-glucoside remained stable 
in both the dried blackberry extract and the dried blackberry 
extract with mannitol stored for 8 weeks at 4° C. Cn-3 
glucoside was continuously lost in the dried blackberry 
extract over 8 week storage at 250 C. After 8 weeks, the 
retained Cn-3 -glucoside was only about 65% of the original. 
In contract, Cn-3-glucoside remained stable in the dried 
blackberry extract with mannitol stored for 8 weeks at 250 C. 
Surprisingly, this suggested that mannitol had a stabilizing 
effect on the dried blackberry extract and in particular Cn-3 
glucoside. As shown in FIG. 5B, this effect was also observed 
for at least three other anthocyanins. FIG. 5B shows the 
stability of Cn-3-glucoside, Cn-3-arabinoside, Cn-3-xylo 
side, and Cn-3-malonyl-glucoside over 8 weeks at 250 C. 
stored as either a dried blackberry extract or dried blackberry 
extract lyophilized in 8% mannitol. 
EXAMPLE 9 
A blackberry extract was obtained by extracting 2.5 g 
blackberry powder (prepared as described in Example 2) 
three times with ethanol/0.01% HCl (see Example 4). The 
three extracts were collected and the ethanol was removed by 
rotoevaporation. Ten (10) mL of water was then used to 
rehydrate the reddish purple extract. One (1) mL of the black 
berry extract was then added to 4 mL of mannitol at a con 
centration of 10%, 5%, 2%, 1%, or 0%. The blackberry 
extract/mannitol samples were then lyophilized as described 
in Example 2. A pink free-?owing powder was only obtained 
with ?nal mannitol concentration of >8%. The pH of the 
blackberry extract/mannitol mixture was in the range of pH 
2.5 to 2.6. Freeze-drying of the blackberry extract in ?nal 
mannitol concentrations less than 2% resulted in a sticky 
gelatin-like product. 
EXAMPLE 10 
A vanishing lotion base having the composition presented 
in Table 6 was prepared by heating a water phase to 70° C. An 










